Scientists and studies have long found that people of all ages who are regularly touched tend to be less anxious, recover ...

Light therapy is emerging as a promising, non-pharmacological treatment for Alzheimer’s disease, offering significant ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Are massage or touch therapies beneficial to individuals with Alzheimer’s disease? Italian Renaissance artist Michelangelo once said, “To touch is to give life.” Scientists and studies have ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Statins help people manage high cholesterol levels, but many experts want to know if these drugs can also support brain ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Pioneering musicians are trialling a radical approach that takes treatment beyond medicine – and could save the NHS millions ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.